# Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

> **NCT04627740** · PHASE1,PHASE2 · COMPLETED · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 5 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Retroviral vector-transduced autologous T cells to express anti-ALPP CARs

## Key facts

- **NCT ID:** NCT04627740
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-08-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627740, "Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04627740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*